Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:address |
12400 High Bluff Drive, Suite 600, San Diego, CA 92130, USA
|
| gptkbp:CEO |
gptkb:Saundra_Pelletier
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
non-hormonal contraception
women's sexual and reproductive health |
| gptkbp:foundedYear |
2007
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Evofem Biosciences
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:notableProduct |
gptkb:Phexxi
|
| gptkbp:product |
gptkb:Phexxi
|
| gptkbp:productType |
contraceptive gel
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:regulates |
FDA approval for Phexxi in 2020
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:EVFM
|
| gptkbp:website |
https://www.evofem.com/
|
| gptkbp:bfsParent |
gptkb:Saundra_Pelletier
|
| gptkbp:bfsLayer |
6
|